Chronic obstructive pulmonary disease (COPD) is one of the leading causes of morbidity and mortality in the world. In the majority of cases, the disease is the result of years of cigarette smoking. Contributing factors leading to bronchial obstruction in COPD include mucus hypersecretion and an increase in bronchial muscle tone, which is triggered mainly by cholinergic mechanisms. Anticholinergic bronchodilators reduce vagal cholinergic tone, the main reversible component of COPD; hence they are the first-line treatment for bronchial obstruction in COPD. In addition to improving lung function, anticholinergics improve dyspnea, quality of life and exercise tolerance, and they reduce exacerbations. When compared with other bronchodilators, anticholinergics show at least equivalent bronchodilator potency, but with fewer side effects. In addition, due to their unique site of action, anticholinergics can be effectively combined with other bronchodilators. The introduction of new, long-acting anticholinergics is a promising addition to the treatment of COPD and is expected to lead to improved treatment outcomes and improved patient compliance.

Keywords:
Chronic obstructive pulmonary disease, Anticholinergics, β-Agonists
1.
Ipratropium bromide; in Dollery C (ed): Therapeutic Drugs. Edinburgh, Livingstone, 1991, pp 168–170.
2.
Oxitropium bromide; in Dollery C (ed): Therapeutic Drugs. Edinburgh, Livingstone, 1991, pp 149–152.
3.
Adams PF, Marano MA: Current estimates from the National Health Interview Survey, 1994. Vital Health Stat 1995;10(193)81–82.
4.
American Thoracic Society Executive Workshop Summary: Global Initiative for chronic obstructive lung disease (GOLD). Am J Respir Crit Care Med 2001;163:1256–1276.
5.
Ashutosh K, Dev G, Steele D: Nonbronchodilator effects of pirbueterol and ipratropium in chronic obstructive pulmonary disease. Chest 1995;107:173–178.
6.
Barnes PJ: Neural control of human airways in health and disease. Am Rev Respir Dis 1986;134:1289–1314.
7.
Barnes PJ: Rationale for the use of antimuscarinics in obstructive airway disease. Rev Contemp Pharmacother 1992;3:173–182.
8.
Barnes PJ: Muscarinic receptor subtypes in airways. Life Sci 1993;52:521–527.
9.
Barnes PJ: The pharmacological properties of tiotropium. Chest 2000;117(suppl):63S–66S.
10.
Barnes PJ, Belvisi MG, Mak JCW, Haddad E, O’Connor BJ: Tiotropium bromide (Ba 679 BR), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease. Life Sci 1995;56:853–859.
11.
Bauer R: The pharmacology of oxitropium bromide. Rev Contemp Pharmacother 1992;3:197–203.
12.
Bleecker ER, Britt EJ: Acute bronchodilating effects of ipratropium bromide and theophylline in chronic obstructive pulmonary disease. Am J Med 1991;91:24S-27S.
13.
Blosser SA, Maxwell SL, Reeves-Hoche MK, Localio AR, Zwillich CW: Is an anticholinergic agent superior to a beta-agonist in improving dyspnea and exercise limitation in COPD? Chest 1995;108:730–735.
14.
Braun SR, Levy SF, Grossman J: Comparison of ipratropium bromide and albuterol in chronic obstructive pulmonary disease: A three-center study. Am J Med 1991;91:28S–32S.
15.
Calverley PMA: The future for tiotropium. Chest 2000;117:67S–69S.
16.
Casaburi R, Briggs DD, Donohue JF: The spirometric efficacy of once-daily dosing with tiotropium in stable COPD. Chest 2000;118:1294–1302.
17.
Cazzola M, Di Perna F, Centanni S, et al: Acute effect of pretreatment with single conventional dose of salmeterol on dose-response curve to oxitropium bromide in chronic obstructive pulmonary disease. Thorax 1999;54:1083–1086.
18.
Cazzola M, Matera MG, Di Perna F, Calderaro F, Califano C, Vinciguerra A: A comparison of bronchodilating effects of salmeterol and oxitropium bromide in stable chronic obstructive pulmonary disease. Respir Med 1998;92:354–357.
19.
Colice GL: Nebulized bronchodilators for outpatient management of stable chronic obstructive pulmonary disease. Am J Med 1996;100:11S–18S.
20.
COMBIVENT Inhalation Aerosol Study Group: In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. Chest 1994;105:1411–1419.
21.
Creemers JPHM, Vincken W, van Noord JA, et al: Tiotropium (TIO) reduces the incidence of COPD exacerbations compared to ipratropium (IB). Presented at the 10th ERS Conference, Florence, Italy 2000. Eur Respir J 2000;16(suppl 31):54s.
22.
Disse B, Speck GA, Rominger KL, et al: Tiotropium (Spiriva): Mechanistical considerations and clinical profile in obstructive lung disease. Life Sci 1999;64:457–464.
23.
Dolcetti A, Moschini MT, Albano A, et al: Comparison of the bronchodilator effect of aminophylline and ipratropium bromide in COPD (abstract). Eur Respir J 1996;9:28s.
24.
Dompeling E, Van Schayck CP, Molema J, et al: A comparison of six different ways of expressing the bronchodilating response in asthma and COPD; reproducibility and dependence of prebronchodilator FEV1. Eur Respir J 1992;5:975–981.
25.
Dorinsky PM, Reisner C, Ferguson GT, et al: The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD. Chest 1999;115:966–971.
26.
Easton PA, Jadue C, Dhingra S, Anthonisen NR: A comparison of the bronchodilating effects of a beta-2 adrenergic agent (albuterol) and an anticholinergic agent (ipratropium bromide), given by aerosol or in sequence. N Engl J Med 1986;315:735–739.
27.
Ferguson GT, Cherniack RM: Management of chronic obstructive pulmonary disease. N Engl J Med 1993;328:1017–1022.
28.
Friedman M: A multicenter study of nebulized bronchodilator solutions in chronic obstructive pulmonary disease. Am J Med 1996;100:30S–39S.
29.
Friedman M, Serby CW, Menjoge SS, et al: Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 1999;115:635–641.
30.
Gandevia B: Historical view of the use of parasympatholytic agents in the treatment of respiratory disorders. Postgrad Med J 1975;51(suppl):13–20.
31.
Greefhorst APM, Vincken W, van Noord JA, et al: Improvement in perceived dyspnea in patients receiving tiotropium vs ipratropium bromide (Atrovent®). 10th ERS Conference, Florence, 2000. Eur Respir J 2000;16(suppl 31):54s.
32.
Gross NJ: Ipratropium bromide. N Engl J Med 1988;319:486–494.
33.
Gross NJ: Safety and side-effects of anticholinergic bronchodilators; in Gross NJ (ed): Anticholinergic Therapy in Obstructive Airways Disease. London; Franklin, 1992;pp 116–127.
34.
Gross NJ, Skorodin MS: Anticholinergic, antimuscarinic bronchodilators. Am Rev Respir Dis 1984;129:856–870.
35.
Haddad E, Mak JCW, Barnes PJ: Characterization of [3H] Ba 679 BR, a slowly dissociating muscarinic antagonist, in human lung: Radioligand binding and autoradiographic mapping. Mol Pharmacol 1994;45:899–907.
36.
Hay JG, Stone P, Carter J, et al: Bronchodilator reversibility, exercise performance and breathlessness in stable chronic obstructive pulmonary disease. Eur Respir J 1992;5:659–664.
37.
Heimer D, Brami JL, Liberman D, Bark H: Comparison of a β2-adrenergic agonist and an anticholinergic agent given by sequential inhalation in patients with severe chronic obstructive pulmonary disease. Isr J Med Sci 1991;27:307–310.
38.
Ikeda A, Nishimura K, Koyama H, Izumi T: Bronchodilating effects of combined therapy with clinical dosages of ipratropium bromide and salbutamol for stable COPD. Chest 1995;107:401–405.
39.
Ikeda A, Nishimura K, Koyama H, Izumi T: Comparative dose-response study of three anticholinergic agents and fenoterol using a metered dose inhaler in patients with chronic obstructive pulmonary disease. Thorax 1995;50:62–66.
40.
Imhof E, Elsasser S, Karrer W, et al: Comparison of bronchodilator effects of fenoterol/ipratropium bromide and salbutamol in patients with chronic obstructive lung disease. Respiration 1993;60:84–88.
41.
John M, Hirst SJ, Jose PJ, et al: Human airway smooth muscle cells express and release RANTES in response to T helper 1 cytokines: Regulation by T helper 2 cytokines and corticosteroids. J Immunol 1997;158:1841–1847.
42.
Karpel JP: Bronchodilator responses to anticholinergic and beta-adrenergic agents in acute and stable COPD. Chest 1991;99:871–876.
43.
Karpel JP, Kotch A, Zinny M, et al: A comparison of inhaled ipratropium, oral theophylline plus inhaled β-agonist, and the combination of all three in patients with COPD. Chest 1994;105:1089–1094.
44.
Karpel JP, Pesin J, Greenberg D, Gentry E: A comparison of the effects of ipratropium bromide and metaproterenol sulfate in acute exacerbations of COPD. Chest 1990;98:835–839.
45.
Kindman LA, Vagelos RH, Willson K, et al: Abnormalities of pulmonary function in patients with congestive heart failure, and reversal with ipratropium bromide. Am J Cardiol 1994;73:258–262.
46.
Koyama H, Nishimura K, Ikeda A, Izumi T: A comparison of the bronchodilating effects of oxitropium bromide and fenoterol in patients with chronic obstructive pulmonary disease. Chest 1993;104:1743–1747.
47.
Maesen FPV, Smeets JJ, Costongs MAL, Wald FDM, Cornelissen PJG: Ba 679 BR, a new long-acting antimuscarinic bronchodilator: A pilot dose-escalation study in COPD. Eur Respir J 1993;6:1031–1036.
48.
Maesen FPV, Smeets JJ, Sledsens TJH, et al: Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: A pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Eur Respir J 1995;8:1506–1513.
49.
Mahler DA, Donohue JF, Barbee RA, et al: Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999;115:957–965.
50.
Mak JC, Baraniuk JN, Barnes PJ: Localization of muscarinic receptor subtype mRNAs in human lung. Am J Respir Cell Mol Biol 1992;7:344–348.
51.
Mak JC, Haddad EB, Buckley NJ, Barnes PJ: Visualization of muscarinic M4 mRNA and M4 receptor subtypes in rabbit lung. Life Sci 1993;53:1501–1508.
52.
Martin RJ, Bartelson BL, Smith P, et al: Effect of ipratropium bromide treatment on oxygen saturation and sleep quality in COPD. Chest 1999;115:1338–1345.
53.
Masa JF, Miravitlles M, Gabriel R: Underdiagnosis and geographic differences in COPD prevalence in Spain. Am J Respir Crit Care Med 1999;159:A9321.
54.
National Heart, Lung, and Blood Institute: Morbidity & Mortality: 2000 Chartbook on Cardiovascular, Lung, and Blood Diseases. US Department of Health and Human Service, 2000.
55.
Newnham DM, Clark RA, Dhillon DP, et al: Bronchodilator reversibility to low and high doses of terbutaline and ipratropium in COPD. Thorax 1992;47:255–256.
56.
Newnham DM, Dhillon DP, Winter JH, et al: Bronchodilator reversibility to low and high doses of terbutaline and ipratropium bromide in patients with chronic obstructive pulmonary disease. Thorax 1993;48:1151–1155.
57.
Nisar M, Earis JE, Pearson MG, Calverley PMA: Acute bronchodilator trials in chronic obstructive pulmonary disease. Am Rev Respir Dis 1992;146:555–559.
58.
Nishimura K, Koyama H, Ikeda A, Izumi T: Is oral theophylline effective in combination with both inhaled anticholinergic and inhaled β-agonist in the treatment of stable COPD? Chest 1993;104:179–184.
59.
O’Byrne PM, Postma DS: The many faces of airway inflammation. Asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;159:S41–S63.
60.
O’Donnell DE, Lam M, Webb KA: Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:542–549.
61.
Patakas D, Andreadis D, Mavrofridis E, Argyropoulou P: Comparison of the effects of salmeterol and ipratropium bromide on exercise performance and breathlessness in patients with stable chronic obstructive pulmonary disease. Respir Med 1998;92:1116–1121.
62.
Rasche K, Strunk M, Holtmann BJ, et al: Pulmo cardialis: Effekt inhalativer Bronchodilatatoren auf den Atemwegswiderstand bei akuter linksventrikulärer Funktionsstörung. Pneumologie 1990;44:S533–S535.
63.
Rennard SI, Serby CW, Ghafouri M, Johnson PA, Friedmann MA: Extended therapy with ipratropium is associated with improved lung function in patients with COPD. Chest 1996;110:62–70.
64.
Rudolf M: Definitions in respiratory disease: The ‘not simply asthmatic’ patient. Rev Contemp Pharmacother 1992;3:183–187.
65.
Schwabl H, Schwabl U, Ulmer WT: The bronchospasmolytic test with anticholinergic drugs and sympathomimetics: Differences between body plethysmography and spirometry measuring procedures. Pneumologie 1990;44(suppl 1):360–361.
66.
Seider N, Abinader EG, Oliven A: Cardiac arrhythmias after inhaled bronchodilators in patients with COPD and ischemic heart disease. Chest 1993;104:1070–1074.
67.
Sherrill DL, Lebowitz MD, Burrows B: Epidemiology of chronic obstructive pulmonary disease. Clin Chest Med 1990;11:375–388.
68.
Shrestha M, O’Brien T, Haddox R, et al: Decreased duration of emergency department treatment of chronic obstructive pulmonary disease exacerbations with the addition of ipratropium bromide to β-agonist therapy. Ann Emerg Med 1991;20:1206–1209.
69.
Siafakas NM: ERS Consensus Statement: Optimal assessment and management of COPD. Eur Resp Rev 1996;6:270–275.
70.
Sichletidis I, Kottakis J, Marcou S, et al: Bronchodilatory responses to formoterol, ipratropium, and their combination in patients with stable COPD. Int J Clin Pract 1999;53:185–188.
71.
Takahashi T, Belvisi MG, Patel H, et al: Effect of Ba 679 BR, a novel long-acting anticholinergic agent, on cholinergic neurotransmission in guinea pig and human airways. Am J Respir Crit Care Med 1994;150:1640–1645.
72.
Tashkin DP, Ashutosh K, Bleecker ER, et al: Comparison of the anticholinergic bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pulmonary disease. Am J Med 1986;81:81–90.
73.
Teramoto S, Matsuse T, Ouchi Y, Fukuchi Y: Influence of 1-year treatment period on responses to anticholinergic inhalation in patients with chronic obstructive pulmonary disease. Curr Ther Res 1997;58:78–87.
74.
Teramoto S, Matsuse T, Sudo E, et al: Long-term effects of inhaled anticholinergic drug on lung function, dyspnea, and exercise capacity in patients with chronic obstructive pulmonary disease. Intern Med 1996;35:772–778.
75.
The COMBIVENT Inhalation Solution Study Group: Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest 1997;112:1514–1521.
76.
Thurlbeck WM: Pathology of chronic obstructive pulmonary disease. Clin Chest Med 1990;11:389–404.
77.
Tsukino M, Nishimura K, Ikeda A, Hajiro T, Koyama H, Izumi T: Effects of theophylline and ipratropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease. Thorax 1998;53:269–273.
78.
Ullmer E, Soler M, Hamm H, Perruchoud AP: Pathogenese, Diagnostik und Therapie der COPD. Pneumologie 2000;54:123–132.
79.
Ulmer WT, Holtmann BJ, Schmidt EW, Schott D: Anticholinergics as bronchodilators. An action profile. Arzneimittelforschung 1987;37:1185–1192.
80.
Van Noord JA, Bantje TA, Eland ME, Korducki L, Cornelissen PJG: A randomized controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. Thorax 2000;55:289–294.
81.
Wahl D, Hammer R: Pharmacokinetics of oxitropium bromide. Rev Contemp Pharmacother 1992;3:205–217.
82.
Weiner N: Atropine, scopolamine and related antimuscarinic drugs; in Gilman AG, Goodman LS, Gilman A (eds): The Pharmacologic Basis of Therapeutics. New York, Macmillan, 1980, pp 135–150.
83.
Wesseling G, Mostert R, Wouters EFM: A comparison of the effects of anticholinergic and β-agonist and combination therapy on respiratory impedance in COPD. Chest 1992;101:166–173.
84.
Witek TJ, Souhrada JF, Serby CW, Disse B: Tiotropium (Ba 679): Pharmacology and early clinical observations; in Spector SS (ed): Anticholinergic Agents in the Upper and Lower Airways. New York, Dekker, 1999, pp 137–152.
85.
ZuWellack R, Jones PW, Kotch A, et al: Tiotropium (Spiriva®) improves health status in patients with COPD. Conference of the ATS, Toronto, 2000. Am J Respir Crit Care Med 2000;16:A892.
86.
Donohue JF, van Noord JA, Langley SJ, Lee A, Kesten S, Towse LJ: Superior bronchodilation of once daily tiotropium compared to twice daily salmeterol in patients with COPD (abstract). Eur Respir J 2001;18:26s.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.